Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGLZ26)

Drug Name

Practolol Drug Info

Synonyms

Dalzic; Eraldin; Practololo; Practololum; Praktololu; Teranol; Eralzdin Practolol; Practololo [DCIT]; Praktololu [Polish]; AY 21011; Cardiol (TN); Cordialina (TN); Dalzic (TN); Eraldin (TN); Eraldina (TN); Practololum [INN-Latin]; Praktol (TN); Pralon (TN); Teranol (TN); Practolol [USAN:BAN:INN]; N-{4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide; N-[4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl]acetamide; N-[4-({2-hydroxy-3-[(1-methylethyl)amino]propyl}oxy)phenyl]acetamide; N-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}acetamide; N-(4-(2-Hydroxy-3-((1-methylethyl)amino)propoxy)phenyl)acetamide; (+-)-Practolol; 1-(4-Acetamidophenoxy)-3-isopropylamino-2-propanol; 4'-(2-Hydroxy-3-(isopropylamino)propoxy)acetanilide

Indication

Disease Entry	ICD 11	Status	REF
Cardiac arrhythmias	BC9Z	Approved	[1]

Therapeutic Class

Antiarrhythmic Agents

Cross-matching ID

PubChem CID: 4883
ChEBI ID: CHEBI:258351
CAS Number: CAS 6673-35-4
TTD Drug ID: DMGLZ26
INTEDE Drug ID: DR1318

Molecule-Related Drug Atlas

Molecule Type:

DTT

DME

DOT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Adrenergic receptor beta-1 (ADRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[5]
Epinephrine	DM3KJBC	Acute asthma	CA23	Approved	[6]
Norepinephrine	DMOUC09	Alopecia	ED70	Approved	[7]
Atenolol	DMNKG1Z	Angina pectoris	BA40	Approved	[8]
Acebutolol	DM0TI4U	Hypertension	BA00-BA04	Approved	[8]
Metoprolol	DMOJ0V6	Acute coronary syndrome	BA41	Approved	[8]
Timolol	DM3NXRU	High blood pressure	BA00	Approved	[9]
Isoproterenol	DMK7MEY	Atrioventricular block		Approved	[10]
Betaxolol	DM6EUL5	Hypertension	BA00-BA04	Approved	[11]
Sotalol	DML60TN	Sinus rhythm disorder	BC9Y	Approved	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[13]
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[14]
Tamoxifen	DMLB0EZ	Breast cancer	2C60-2C65	Approved	[15]
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[16]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[17]
Quinine	DMSWYF5	Malaria	1F40-1F45	Approved	[18]
Propofol	DMB4OLE	Anaesthesia	9A78.6	Approved	[19]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[20]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[21]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[22]
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[23]
Paliperidone	DM7NPJS	Psychotic disorder	6A20-6A25	Approved	[24]
Dopamine	DMPGUCF	Acromegaly	5A60.0	Approved	[25]
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[26]
Oxatomide	DM1F42Z	Hay fever	CA08.00	Approved	[27]
Cinacalcet	DMCX0K3	Hyperparathyroidism	5A51	Approved	[28]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[29]
Pentamidine	DMHZJCG	African trypanosomiasis	1F51	Approved	[30]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[31]
Buprenorphine	DMPRI8G	Opioid dependence	6C43.2Z	Approved	[32]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic receptor beta-1 (ADRB1)	TTR6W5O	ADRB1_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)^{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[3]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 2D6 (CYP2D6)	OTZJC802	CP2D6_HUMAN	Drug Response	[4]

------------------------------------------------------------------------------------

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 555).
2	Prostaglandin E2 synthesis elicited by adrenergic stimuli in guinea pig trachea is mediated primarily via activation of beta 2 adrenergic receptors. Prostaglandins. 1992 Nov;44(5):399-412.
3	Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432.
4	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
5	Beta-blockers in the treatment of hypertension: are there clinically relevant differences Postgrad Med. 2009 May;121(3):90-8.
6	Adrenergic activation of electrogenic K+ secretion in guinea pig distal colonic epithelium: involvement of beta1- and beta2-adrenergic receptors. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G269-77.
7	Impact of exogenous beta-adrenergic receptor stimulation on hepatosplanchnic oxygen kinetics and metabolic activity in septic shock. Crit Care Med. 1999 Feb;27(2):325-31.
8	Prediction and experimental validation of acute toxicity of beta-blockers in Ceriodaphnia dubia. Environ Toxicol Chem. 2005 Oct;24(10):2470-6.
9	Topical dorzolamide 2%/timolol 0.5% ophthalmic solution: a review of its use in the treatment of glaucoma and ocular hypertension. Drugs Aging. 2006;23(12):977-95.
10	Current therapeutic uses and potential of beta-adrenoceptor agonists and antagonists. Eur J Clin Pharmacol. 1998 Feb;53(6):389-404.
11	beta-adrenergic enhancement of brain kynurenic acid production mediated via cAMP-related protein kinase A signaling. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Apr 30;33(3):519-29.
12	beta(2)-adrenoceptors are critical for antidepressant treatment of neuropathic pain. Ann Neurol. 2009 Feb;65(2):218-25.
13	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
14	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
15	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
18	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
19	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
20	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
21	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
22	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
23	Human recombinant cytochrome P450 enzymes display distinct hydrogen peroxide generating activities during substrate independent NADPH oxidase reactions. Toxicol Sci. 2014 Oct;141(2):344-52. doi: 10.1093/toxsci/kfu133. Epub 2014 Jul 24.
24	Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology (Berl). 1999 Dec;147(3):300-5. doi: 10.1007/s002130051171.
25	Effect of penicillin-based antibiotics, amoxicillin, ampicillin, and piperacillin, on drug-metabolizing activities of human hepatic cytochromes P450. J Toxicol Sci. 2016 Feb;41(1):143-6.
26	Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos. 2011 Nov;39(11):2049-56. doi: 10.1124/dmd.111.041384. Epub 2011 Aug 5.
27	Identification of human P450 isoforms involved in the metabolism of the antiallergic drug, oxatomide, and its kinetic parameters and inhibition constants. Biol Pharm Bull. 2005 Feb;28(2):328-34.
28	Pharmacokinetics of desipramine HCl when administered with cinacalcet HCl. Eur J Clin Pharmacol. 2007 Feb;63(2):159-63.
29	Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
30	Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
31	Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Clin Pharmacol Ther. 2001 Oct;70(4):327-35.
32	Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metab Dispos. 2003 Jun;31(6):768-72.